RxDoctor Payments Data

David Steiner, MD

Neurology · Woodmere, NYNPI 1467458661

Payments from drug & device makers

$664,439in general payments, 2019–2025

Across 1,101 payments — averaging $603.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$354K
  • E.r. Squibb & Sons, L.L.C.$103K
  • Eisai Inc.$38K
  • Mallinckrodt Hospital Products Inc.$33K
  • Biogen$32K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$22K
  • plus $83K from 54 others
$25,120in research payments, 2019–2025

Across 3 payments — averaging $8373.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$25K

What the payments were for

  • Speaking & faculty fees$31,08056%
  • Food & beverage$23,94143%
  • Education$4431%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis79$353,757
E.r. Squibb & Sons, L.L.C.14$102,736
Eisai Inc.29$38,176
Mallinckrodt Hospital Products Inc.112$33,027
Biogen66$32,021
Otsuka Pharmaceutical Development & Commercialization, Inc.2$21,953
UCB SA3$21,348
Mallinckrodt Enterprises LLC31$19,330
Sage Therapeutics, LLC1$11,200
SK Life Science, Inc.23$7,598
Sanofi41$3,740
H. Lundbeck A S2$3,000
AbbVie(2 entities)112$2,189
Harmony Biosciences LLC74$2,114
ANI Pharmaceuticals, Inc.31$1,200
Genentech USA, Inc.61$948
Bristol Myers Squibb42$927
Biohaven Pharmaceuticals, Inc.12$584
Lilly USA, LLC28$537
Amgen(2 entities)21$464
UCB, Inc.24$454
AstraZeneca(2 entities)10$410
EMD Serono, Inc.17$401
Argenx US, Inc.14$399
Pfizer20$372
Lundbeck LLC15$358
TG Therapeutics, Inc.12$340
Neurocrine Biosciences, Inc.13$337
Sunovion Pharmaceuticals Inc.20$330
Arbor Pharmaceuticals, Inc.18$297
Livanova USA, Inc.10$297
Teva Pharmaceuticals USA, Inc.16$291
Jazz Pharmaceuticals Inc.11$264
Axsome Therapeutics, Inc.10$259
Supernus Pharmaceuticals, Inc.11$210
Johnson & Johnson5$190
ZOLL Respicardia, Inc.2$168
Takeda Pharmaceuticals U.S.A., Inc.6$167
Ipsen Biopharmaceuticals, Inc7$164
Azurity Pharmaceuticals, Inc.8$158
Otsuka America Pharmaceutical, Inc.7$157
Almatica Pharma LLC8$155
Abbott1$144
Biotronik NRO, Inc.1$140
Biohaven Pharmaceutical Holding Company Ltd.6$131
Medtronic(2 entities)3$121
Avanir Pharmaceuticals, Inc.4$92
Scilex Pharmaceuticals Inc.4$83
Vanda Pharmaceuticals Inc.4$83
Corium, LLC4$80
Acorda Therapeutics, Inc4$79
Merz Pharmaceuticals, LLC2$55
Upsher-smith Laboratories LLC3$52
Amneal Pharmaceuticals LLC2$48
Kyowa Kirin, Inc.2$42
GE HealthCare2$32
Neurelis, Inc.1$31
International Rehabilitative Sciences, Inc1$26
Sumitomo Pharma America, Inc.1$25
Catalyst Pharmaceuticals, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$664,439 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$317,934
Medicare patients
262
Services billed
2,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Budesonide ErBudesonide93$303,030
Teriflunomide19$69,262
AptiomEslicarbazepine Acetate34$48,117
Dalfampridine ErDalfampridine40$10,967
Dimethyl Fumarate14$3,605
Oxcarbazepine23$1,819
Tizanidine Hcl198$1,402
Levetiracetam44$1,063
Gabapentin108$1,045
Nabumetone131$960
Donepezil Hcl106$900
Duloxetine Hcl50$627
Topiramate80$609
Memantine Hcl19$594
Meclizine Hcl33$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$330$48,11734 claims
Upsher-smith Laboratories LLCTopiramate$52$60980 claims
Almatica Pharma LLCSertraline Hcl$155$19038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.

Other neurology in Woodmere

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →